Breast Department, KK Women's and Children's Hospital, Singapore, Singapore.
Duke-NUS Medical School, Singapore, Singapore.
Cancer Med. 2020 Mar;9(6):1978-1985. doi: 10.1002/cam4.2848. Epub 2020 Jan 22.
Removal of clipped nodes can improve sentinel node biopsy accuracy in breast cancer patients post neoadjuvant chemotherapy (NACT). However, the current methods of clipped node localization have limitations. We evaluated the feasibility of a novel clipped node localization and removal technique by preoperative skin marking of clipped nodes and removal by the Skin Mark clipped Axillary nodes Removal Technique (SMART), with the secondary aim of assessing the ultrasound visibility of the various clips in the axillary nodes after NACT.
Invasive breast cancer patients with histologically metastatic axillary nodes, going for NACT, and ≤3 sonographically abnormal axillary nodes were recruited. All abnormal nodes had clips inserted. Patients with M1 disease were excluded. Post-NACT, patients underwent SMART and axillary lymph node dissection. Specimen radiography and pathological analyses were performed to confirm the clipped node presence. Success, complication rates of SMART, and ultrasound visibility of the various clips were assessed.
Twenty-five clipped nodes in 14 patients underwent SMART without complications. The UltraCor Twirl, hydroMARK, UltraClip Dual Trigger, and UltraClip were removed in 13/13 (100%), 7/9 (77.8%), 1/2 (50.0%), and 0/1 (0%), respectively (P = .0103) with UltraCor Twirl having the best ultrasound visibility and removal rate. Removal of three clipped nodes in the same patient (P = .0010) and deeply seated clipped nodes (P = .0167) were associated with SMART failure.
Skin Mark clipped Axillary nodes Removal Technique is feasible for removing clipped nodes post-NACT, with 100% observed success rate, using the UltraCor Twirl marker in patients with <3 not deeply seated clipped nodes. Larger studies are needed for validation.
在接受新辅助化疗(NACT)的乳腺癌患者中,切除剪断的淋巴结可以提高前哨淋巴结活检的准确性。然而,目前的剪断淋巴结定位方法存在局限性。我们评估了一种新的剪断淋巴结定位和切除技术的可行性,通过术前剪断淋巴结的皮肤标记和皮肤标记剪断腋窝淋巴结切除技术(SMART)切除,次要目的是评估 NACT 后腋窝淋巴结中各种夹子的超声可见性。
入组了接受新辅助化疗且有组织学转移性腋窝淋巴结、≤3 个超声异常腋窝淋巴结的浸润性乳腺癌患者。所有异常淋巴结均插入了夹子。排除 M1 期疾病患者。NACT 后,患者接受 SMART 和腋窝淋巴结清扫。对标本进行放射摄影和病理分析,以确认剪断的淋巴结存在。评估 SMART 的成功率、并发症发生率以及各种夹子的超声可见性。
14 例患者的 25 个剪断淋巴结行 SMART 手术,无并发症。UltraCor Twirl、hydroMARK、UltraClip Dual Trigger 和 UltraClip 的取出率分别为 13/13(100%)、7/9(77.8%)、1/2(50.0%)和 0/1(0%)(P=0.0103),UltraCor Twirl 的超声可见性和取出率最好。在同一位患者中,有 3 个剪断淋巴结(P=0.0010)和位置较深的剪断淋巴结(P=0.0167)的 SMART 失败率更高。
皮肤标记剪断腋窝淋巴结切除技术在 NACT 后切除剪断的淋巴结是可行的,在<3 个非深部剪断淋巴结且未发现剪断淋巴结的患者中,使用 UltraCor Twirl 标记物,观察到 100%的成功率。需要进一步开展更大规模的研究来验证。